Repositorio Dspace

Listar por tema "Neprilysin"

Listar por tema "Neprilysin"

Ordenar por:Orden:Resultados:

  • Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study 
    Revuelta-López, Elena; Nunez, Julio; Gastelurrutia, Paloma; Cediel, German; Januzzi, James-L; Ibrahim, Nasrien-E; Emdin, Michele; VanKimmenade, Roland; Pascual-Figal, Domingo-Andrés; Nunez, Eduardo; Gommans, Frank; Lupon, Josép; Bayes-Genis, Antoni (WILEY PERIODICALS, INC, 2020-04)
    AIM: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of ...
  • Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension 
    Codina, Pau; Domingo, Mar; Barcelo, Elena; Gastelurrutia, Paloma; Casquete, Daniel; Vila, Joan; Abdul-Jawad-Altisent, Omar; Spitaleri, Giosafat; Cediel, German; Santiago-Vacas, Evelyn; Zamora, Elisabet; Ruiz-Cueto, María; Santesmases, Javier; de-la-Espriella, Rafael; Pascual-Figal, Domingo-A; Nunez, Julio; Lupon, Josep; Bayes-Genis, Antoni (Wiley Periodicals, Inc, 2022-08)
    AIMS: Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary ...